X0306 4 2023-01-06 0 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001891900 Teehan Brendan C/O ACADIA PHARMACEUTICALS INC. 12830 EL CAMINO REAL, SUITE 400 SAN DIEGO CA 92130 0 1 0 0 EVP, COO, Head of Commercial Common Stock 2023-01-06 4 M 0 1286 A 5081 D Common Stock 2023-01-09 4 S 0 532 17.1303 D 4549 D Restricted Stock Units 2022-01-06 4 M 0 1286 0.00 D Common Stock 1286 2573 D Restricted Stock Units 2023-01-06 4 M 0 1286 0.00 D Common Stock 1286 1287 D Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Includes 358 shares of the Issuer's common stock acquired by the reporting person on May 16, 2022 pursuant to an employee stock purchase program. The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.13 to $17.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. This restricted stock units is being re-reported solely to correct vesting terms on the Form 4 filed on January 10, 2022, which erroneously indicated that the restricted stock units vest in four equal annual installments beginning January 6, 2021. The correct vesting is one-third of the shares subject to the restricted stock units vest on each of January 6, 2022, January 6, 2023 and January 6, 2024. Except as noted in this footnote, all other information as disclosed in the Reporting Person's original Form 4 was accurately reported. One-third of the shares subject to the restricted stock units vest on each of January 6, 2022, January 6, 2023 and January 6, 2024. /s/ Austin D. Kim, Attorney-in-Fact 2023-01-10